Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy.

Seclén E, Soriano V, González MM, Martín-Carbonero L, Gellermann H, Distel M, Kadus W, Poveda E.

J Infect Dis. 2011 Jul 1;204(1):139-44. doi: 10.1093/infdis/jir218.

2.

The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.

Santoro MM, Armenia D, Fabeni L, Santoro M, Gori C, Forbici F, Svicher V, Bertoli A, Dori L, Surdo M, Balestra E, Palamara G, Girardi E, Angarano G, Andreoni M, Narciso P, Antinori A, Ceccherini-Silberstein F, Perno CF.

Clin Microbiol Infect. 2012 Aug;18(8):E289-98. doi: 10.1111/j.1469-0691.2012.03905.x. Epub 2012 Jun 8.

3.

HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.

Treviño A, Soriano V, Poveda E, Parra P, Cabezas T, Caballero E, Roc L, Rodríguez C, Eiros JM, Lopez M, De Mendoza C; HIV-2 Spanish Study Group..

J Antimicrob Chemother. 2014 Aug;69(8):2191-4. doi: 10.1093/jac/dku119. Epub 2014 Apr 30.

PMID:
24788659
4.

Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts.

Nozza S, Canducci F, Galli L, Cozzi-Lepri A, Capobianchi MR, Ceresola ER, Narciso P, Libertone R, Castelli P, Moioli M, D'Arminio Monforte A, Castagna A; ICONA Foundation..

J Antimicrob Chemother. 2012 May;67(5):1224-7. doi: 10.1093/jac/dkr600. Epub 2012 Jan 31.

PMID:
22298348
5.

The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.

Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G.

Clin Infect Dis. 2008 May 15;46(10):1617-23. doi: 10.1086/587660.

PMID:
18419499
6.

HIV-1 tropism and CD4 T lymphocyte recovery in a prospective cohort of patients initiating HAART in Ribeirão Preto, Brazil.

Lanca AM, Collares JK, Ferreira JL, Lima DM, Brigido LF, Rodrigues R, Fonseca BA.

Mem Inst Oswaldo Cruz. 2012 Feb;107(1):96-101.

7.

Co-receptor switch during HAART is independent of virological success.

Saracino A, Monno L, Cibelli DC, Punzi G, Brindicci G, Ladisa N, Tartaglia A, Lagioia A, Angarano G.

J Med Virol. 2009 Dec;81(12):2036-44. doi: 10.1002/jmv.21598.

PMID:
19856465
8.

Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.

Ferrer P, Tello M, Montecinos L, Tordecilla R, Rodríguez C, Beltrán C, Guzmán MA, Ferrés M, Pérez CM, Afani A.

J Clin Virol. 2014 Jul;60(3):290-4. doi: 10.1016/j.jcv.2014.04.004. Epub 2014 Apr 15.

PMID:
24793966
9.

Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.

Asmelash A, Zheng Y, Kaloustian KW, Shaffer D, Sawe F, Ogwu A, Salata R, Currier J, Hughes MD, Lockman S.

BMC Infect Dis. 2014 Jun 17;14:331. doi: 10.1186/1471-2334-14-331.

10.

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500  cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.

Soulié C, Charpentier C, Flandre P, Nino C, Carcelain G, Simon A, Katlama C, Landman R, Brun-Vézinet F, Descamps D, Calvez V, Marcelin AG.

J Med Virol. 2012 Dec;84(12):1853-6. doi: 10.1002/jmv.23362.

PMID:
23080487
11.

Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D; ANRS 130 APOLLO Trial Study Group..

J Antimicrob Chemother. 2013 Mar;68(3):690-6. doi: 10.1093/jac/dks455. Epub 2012 Nov 14.

PMID:
23152480
12.

HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.

Soulié C, Marcelin AG, Ghosn J, Amellal B, Assoumou L, Lambert S, Duvivier C, Costagliola D, Katlama C, Calvez V.

AIDS. 2007 Oct 18;21(16):2243-5.

PMID:
18090053
13.

Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.

Dlamini JN, Hu Z, Somaroo H, Highbarger HC, Follmann DA, Dewar RL, Pau AK.

Pharmacotherapy. 2011 Feb;31(2):158-63. doi: 10.1592/phco.31.2.158.

14.

Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.

Wu H, Connick E, Kuritzkes DR, Landay A, Spritzler J, Zhang B, Spear GT, Kessler H, Lederman MM; ACTG 315 Team..

AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1231-40.

PMID:
11559422
15.

Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years.

Briz V, Poveda E, del Mar González M, Martín-Carbonero L, González-González R, Soriano V.

J Antimicrob Chemother. 2008 Feb;61(2):405-10. Epub 2007 Dec 6.

PMID:
18063598
16.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
17.

Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease.

Casadellà M, Manzardo C, Noguera-Julian M, Ferrer E, Domingo P, Pérez-Álvarez S, Podzamczer D, Plana M, Clotet B, Gatell JM, Miró JM, Paredes R; ADVANZ and ADVANZ-3 Investigators..

AIDS. 2015 Jul 31;29(12):1493-504. doi: 10.1097/QAD.0000000000000748.

PMID:
26244389
18.

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).

Miro JM, Manzardo C, Ferrer E, Loncà M, Guardo AC, Podzamczer D, Domingo P, Curran A, Clotet B, Cruceta A, Lozano F, Pérez I, Plana M, Gatell JM; Advanz-3 Study Group..

J Acquir Immune Defic Syndr. 2015 Jun 1;69(2):206-15. doi: 10.1097/QAI.0000000000000567.

PMID:
25831464
19.

Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).

Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P; S 130 Apollo Trial Group..

Antimicrob Agents Chemother. 2013 Feb;57(2):758-65. doi: 10.1128/AAC.01662-12. Epub 2012 Nov 19.

20.

Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW; AIDS Clinical Trials Group 5201 Study Team..

JAMA. 2006 Aug 16;296(7):806-14.

PMID:
16905786

Supplemental Content

Support Center